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LETTERS TO THE EDITOR
Oxymetazoline Hydrochloride
Combined With Mometasone
Nasal Spray for Persistent Nasal
Congestion (Pilot Study)
To the Editor:
Nasal glucocorticosteroids (NGCS) are considered
first-line therapy for allergic rhinitis and are effective therapy
for nonallergic rhinitis, especially vasomotor rhinitis and
nonallergic rhinitis with eosinophilia syndrome.1–4 Nasal
congestion can persist despite maximum treatment with
NGCS. Although oral and topical antihistamines are effec-
tive in relieving this symptom,5,6 neither oral nor topical
antihistamines are as effective in relieving this symptom
compared with NGCS.7,8 Oxymetazoline (OXY) is a de-
congestant and the addition of oxymetazoline to a NGCS
should add a considerable decongestant benefit. However,
its use is recommended only for 3–14 days because of the
risk of rhinitis medicamentosa (RM), increased nasal con-
gestion caused by prolonged use of such drugs.9
NGCS are helpful in reducing the amount of rebound
congestion in patients with perennial allergic rhinitis with
RM. They also decrease nasal mucosal edema, recruitment of
neutrophils and mononuclear cells, cytokine production, and
late-phase nasal mediators. They may offer a protective
benefit from the development of RM. Oxymetazoline may
also decrease turbinate enlargement, thereby permitting better
nasal distribution of NGCS.
Data are limited about efficacy and safety of OXY used
with NGCS for nasal congestion (NC) not adequately re-
sponding to recommended doses of NGCS.
METHODS
Patients had at least a 1-year history of perennial
allergic or nonallergic rhinitis (including vasomotor rhinitis
and nonallergic rhinitis with eosinophilia syndrome) docu-
mented by skin testing in the medical record before study
enrollment. Those receiving allergen immunotherapy were on
a stable maintenance regimen for at least 30 days before the
first study visit and remained on the same dose during the
study. Institutional review board approval and informed con-
sent were obtained before initiation of the study.
Patients completed twice daily diary cards pertaining to
their nasal symptoms: 0 (not noticeable); 1 (mild symptoms,
noticeable but not bothersome); 2 (moderate symptoms, no-
ticeable and disturbing some of the time); 3 (severe symp-
toms, very disturbing some of the time and/or disturbing most
of the time). All had a nasal congestion score of 1.5 or greater
at the screening visit (day 7) and an average nasal congestion
score of 1.5 or greater at the baseline visit (day 1). The
average nasal congestion score was calculated from during
the last 3 days before baseline and the morning of the baseline
visit (i.e., total of 7 scores).10
A 20-day randomized double blind, placebo controlled
pilot study of patients18 years with a minimum 1-year history
of moderate to severe NC that failed to respond to NGCS were
stratified to mometasone nasal spray (MNS) 100 g every night
or nightly and OXY 0.05% 2 sprays per nostril (s/n) 2 times
daily versus MNS 100 g every night or nightly plus saline
placebo (PL) 2 s/n 2 times daily (Fig. 1).
Patients completed diaries for NC and quality of life
(QOL) and underwent intranasal examination for nasal and
turbinate changes and rhinorrhea. Patients continued on
NGCS after study termination.
RESULTS
Twenty-three patients met inclusion criteria. The MNS
plus OXY cohort versusMNS plus PL achieved an averaged NC
score of 1.68 versus 2.06 (NS), respectively (Fig. 2). The
treatment group reported 22% improvement in average daily NC
score on days 5 to 7 (NC score 1.56; 95% confidence interval
[CI] 1.23–1.89); 14.5% on days 12 to 14 (NC score 1.71; 95%
CI 1.39–2.03); 13.5% on days 18 to 20 (NC score 1.73; 95% CI
1.39–2.07); 6.5% post-treatment days 21 to 42 (NC score 1.87;
95% CI 1.56–2.18) versus the MNS plus PL of 1.4% worsening
on days 5 to 7 (NC score 2.16; 95%CI 1.94–2.38); 9.4% improve-
ment on days 12 to 14 (NC score 1.93; 95% CI 1.64–2.22); 6.6%
improvement on days 18 to 20 (NC score 1.99; 95%CI 1.61–2.37);
and 5.8% improvement post-treatment days 21 to 42 (NC score
1.92; 95% CI 1.55–2.29). With use of Kolmogorov-Smirnov sta-
tistical analysis, the P value comparing the 2 groups on days 18 to
20was 0.12. Slightly more nasal erythema occurred with OXY. No
RM or other side effects occurred in either group.
The Mini Rhinoconjunctivitis Quality of Life Question-
naire (Mini RQLQ) is stratified into 5 categories: activities,
practical problems, nose symptoms, eye symptoms, and other
symptoms. Patients rate symptoms from 0 (not troubled) to 6
(extremely troubled).
Among the 5 Mini RQLQ indicators, the MNS plus
OXY cohort reported the biggest benefit on activity mea-
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sures, P  0.04 (Fig. 3). The treatment group reported 36%
improvement in ability to do regular activities at home/work
on days 6 to 10; 45% improvement on days 13 to 20 versus
the MNS plus PL 11% improvement on days 6 to 10; 31%
improvement on days 13 to 20. Patients in the MNS plus
OXY cohort noted improvement in the ability to do recre-
ational activities by 28% on days 6 to 10; 57% improvement
on days 13 to 20 versus 15% improvement on days 6 to 10;
22% improvement on days 13 to 20 in the MNS plus PL
cohort. Among the activity benefits, sleep improvement was
comparatively most consistently beneficial in the MNS plus
OXY cohort with 17% improvement on days 6 to 10; 28% on
days 13 to 20 versus 4% improvement on days 6 to 10; 2%
worsening on days 13 to 20 in the MNS plus PL cohort.
CONCLUSIONS
MNS plus OXY combination for 20 days decreases
NC and improves activity QOL indicators without signif-
icant side effects or risk for RM. Most Mini RQLQ data
are not statistically significant. However, quality of life
activity measures are statistically significant with sleep
improvement most notable. Relief of nasal congestion
trends toward improvement both in nasal congestion scores
and QOL scores. It is unclear why most improvement is
seen on days 5 to 7. A larger study powered with 145
patients is necessary to prove statistically the effectiveness
and safety of these 2 medications used together. There are
several papers presented at the American Academy of
Allergy Asthma and Immunology, New Orleans, 2010,
meeting which demonstrate effectiveness of MNS plus
OXY versus one or the other without appreciable side
effects.11–13 It is demonstrated in single-blind control stud-
ies that the combination of MNS plus OXY versus either
one alone is tolerated and more effective in relieving
symptoms of rhinitis. Parameters shown to respond to this
combination versus one or the other or placebo include
improved onset of action, better relief of nasal congestion,
and improved quality of life without any increase in
adverse events either during treatment or after such treat-
ment is discontinued.11–13
Efren L. Rael, MD
John Ramey, MD
Richard F. Lockey, MD
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